ALT vs TECX
ALT: Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a dual GLP-1/glucagon agonist, to treat serious liver and metabolic disorders. TECX: A clinical-stage biotechnology company developing GPCR-targeted biologic medicines for diseases with significant unmet medical needs.
Side-by-side fundamentals
| Metric | ALT | TECX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.60 | $22.75 | |
| Market cap | $506M | $445M | |
| Net margin FY2025, SEC XBRL | -214861.0% | n/a | |
| Operating margin FY2025, SEC XBRL | -230461.0% | n/a | |
| ROE FY2025, SEC XBRL | -39.2% | -29.5% | TECX higher |
| ROA FY2025, SEC XBRL | -31.5% | -28.4% | TECX higher |
| Debt / equity as of 2026-09-03 | 0.12 | 0.00 | TECX lower |
| Revenue growth (YoY) as of 2026-09-03 | +80.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 1.55 | 1.59 | |
| 1-year return as of 2026-10-08 close | -33.8% | +48.1% | TECX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.